1. Home
  2. SVV vs WGS Comparison

SVV vs WGS Comparison

Compare SVV & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Savers Value Village Inc.

SVV

Savers Value Village Inc.

HOLD

Current Price

$9.93

Market Cap

1.4B

ML Signal

HOLD

Logo GeneDx Holdings Corp.

WGS

GeneDx Holdings Corp.

HOLD

Current Price

$65.35

Market Cap

1.2B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
SVV
WGS
Founded
1954
2017
Country
United States
United States
Employees
N/A
1300
Industry
Other Specialty Stores
Retail: Computer Software & Peripheral Equipment
Sector
Consumer Discretionary
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.2B
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
SVV
WGS
Price
$9.93
$65.35
Analyst Decision
Buy
Strong Buy
Analyst Count
6
7
Target Price
$13.67
$120.71
AVG Volume (30 Days)
788.1K
829.7K
Earning Date
05-06-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,678,954,000.00
N/A
Revenue This Year
$6.91
$29.98
Revenue Next Year
$7.80
$25.92
P/E Ratio
N/A
$1,251.58
Revenue Growth
9.19
N/A
52 Week Low
$6.91
$32.21
52 Week High
$13.89
$170.87

Technical Indicators

Market Signals
Indicator
SVV
WGS
Relative Strength Index (RSI) 56.21 53.59
Support Level $9.27 $55.76
Resistance Level $10.15 $73.21
Average True Range (ATR) 0.39 4.13
MACD -0.07 -0.79
Stochastic Oscillator 51.17 39.81

Price Performance

Historical Comparison
SVV
WGS

About SVV Savers Value Village Inc.

Savers Value Village Inc is a for-profit thrift operator in the United States and Canada. It purchases second-hand textiles (i.e., clothing, bedding, and bath items), shoes, accessories, housewares, books, and other goods from its non-profit partners (NPPs), either directly from them or via on-site donations (OSDs) at Community Donation Centers at its stores. The company then processes, selects, prices, and sells these items in its stores.

About WGS GeneDx Holdings Corp.

GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.

Share on Social Networks: